# BAL0891

Source: https://onco.cc/drugs/bal0891/  
OnCo record `bal0891` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BAL0891 is an experimental medicine from SillaJen that blocks two enzymes cancer cells use to divide. It is in an early trial, and the FDA has given it orphan drug status for acute myeloid leukaemia.

## Summary

BAL0891 is a small molecule developed by SillaJen that inhibits threonine tyrosine kinase (TTK, also called MPS1) and polo-like kinase 1 (PLK1). The company describes the two effects as mitotic override (TTK) and mitotic block at G2/M (PLK1), both leading to cancer cell death, and its pipeline page cites a 2022 Basilea presentation as a source. It is in a phase 1 trial, NCT05768932, in advanced solid tumours and relapsed or refractory acute myeloid leukaemia. The FDA granted orphan drug designation on 24 August 2026 for the treatment of acute myeloid leukaemia; the database record describes the product as a small-molecule mitotic checkpoint inhibitor with dual TTK and PLK1 inhibition.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Tags: pipeline; orphan-designation
- Code: BAL0891
- Modality: Small-molecule kinase inhibitor
- Mechanism: A mitotic checkpoint inhibitor that blocks two kinases, TTK (MPS1) and PLK1: blocking TTK lets cancer cells divide before their chromosomes are properly attached, and blocking PLK1 stops them at the G2/M phase, as the developer describes it.

## Sources

- SillaJen: BAL0891: https://www.sillajen.com/eng/sub/pipeline_bal0891.html
- FDA orphan designation record: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1162426
- ClinicalTrials.gov: NCT05768932: https://clinicaltrials.gov/study/NCT05768932

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- targets: [MPS1 (TTK)](https://onco.cc/targets/ttk/), [PLK1](https://onco.cc/targets/plk1/)
- companies: [SillaJen](https://onco.cc/companies/sillajen/)

---
JSON: https://onco.cc/api/v1/entities/bal0891.json